Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8435280 | 0.82 | CNR2 (0.47) | CNR2CNR1ALDH1A1HRH3MYC | |
| SCHEMBL14367676 | 0.74 | AOC3 (0.47) | CNR2PANK3ALDH1A1HRH3MEN1 | |
| SCHEMBL8252773 | 0.73 | AOC3 (0.48) | CNR2PANK3CNR1ALDH1A1MEN1 | |
| SCHEMBL20797611 | 0.71 | KCNJ1 (0.46) | CNR2CNR1ALDH1A1MYCMEN1 | |
| SCHEMBL20797535 | 0.71 | KCNJ1 (0.46) | CNR2CNR1ALDH1A1MYCMEN1 | |
| SCHEMBL20797345 | 0.71 | KCNJ1 (0.46) | CNR2CNR1ALDH1A1MYCMEN1 | |
| SCHEMBL20810916 | 0.71 | KCNJ1 (0.46) | CNR2CNR1ALDH1A1MYCMEN1 | |
| SCHEMBL8245080 | 0.71 | CYP11B1 (0.56) | CNR2PANK3ALDH1A1MEN1KMT2A | |
| SCHEMBL345439 | 0.71 | ENPP2 (0.45) | ABL1PANK3HRH3MEN1KMT2A | |
| SCHEMBL17229276 | 0.71 | PARP1 (0.54) | CNR2PANK3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | CNR2 3169/4885ABL1 3874/4885PANK3 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.